Progress in clinical research on the integration of Chinese and Western medicines for treating primary liver cancer

Primary liver cancer (PLC) is one of the most common malignant tumors in China. PLC is characterized by insidious onset, rapid progress, poor quality of life, and short survival time. Notably, current treatment strategies remain unsatisfactory. Traditional Chinese medicines (TCM) have been used to t...

Full description

Bibliographic Details
Main Authors: Kaiqi Liu, Hongliang Li, Jufeng Duan, Xiaojing Chen, Xiongjie Yu, Xianhe Wang, Ming Liu, Bei Li, Minglun Li, Yibin Feng, Xiaojun Cai, Xuanbin Wang
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:Journal of Traditional Chinese Medical Sciences
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2095754821000442
id doaj-7252d3e2ffe44d9b8a836564a1e18de3
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Kaiqi Liu
Hongliang Li
Jufeng Duan
Xiaojing Chen
Xiongjie Yu
Xianhe Wang
Ming Liu
Bei Li
Minglun Li
Yibin Feng
Xiaojun Cai
Xuanbin Wang
spellingShingle Kaiqi Liu
Hongliang Li
Jufeng Duan
Xiaojing Chen
Xiongjie Yu
Xianhe Wang
Ming Liu
Bei Li
Minglun Li
Yibin Feng
Xiaojun Cai
Xuanbin Wang
Progress in clinical research on the integration of Chinese and Western medicines for treating primary liver cancer
Journal of Traditional Chinese Medical Sciences
Traditional Chinese medicines
Primary liver cancer
Integrative medicine
Clinical research
author_facet Kaiqi Liu
Hongliang Li
Jufeng Duan
Xiaojing Chen
Xiongjie Yu
Xianhe Wang
Ming Liu
Bei Li
Minglun Li
Yibin Feng
Xiaojun Cai
Xuanbin Wang
author_sort Kaiqi Liu
title Progress in clinical research on the integration of Chinese and Western medicines for treating primary liver cancer
title_short Progress in clinical research on the integration of Chinese and Western medicines for treating primary liver cancer
title_full Progress in clinical research on the integration of Chinese and Western medicines for treating primary liver cancer
title_fullStr Progress in clinical research on the integration of Chinese and Western medicines for treating primary liver cancer
title_full_unstemmed Progress in clinical research on the integration of Chinese and Western medicines for treating primary liver cancer
title_sort progress in clinical research on the integration of chinese and western medicines for treating primary liver cancer
publisher Elsevier
series Journal of Traditional Chinese Medical Sciences
issn 2095-7548
publishDate 2021-07-01
description Primary liver cancer (PLC) is one of the most common malignant tumors in China. PLC is characterized by insidious onset, rapid progress, poor quality of life, and short survival time. Notably, current treatment strategies remain unsatisfactory. Traditional Chinese medicines (TCM) have been used to treat a variety of diseases, including liver diseases, for more than 2000 years. In this study, we performed a review of the use frequency and clinical efficacy of TCM in treating PLC. Relevant literature from January 1, 2009, to January 1, 2021 was retrieved from network databases of China National Knowledge Infrastructure (CNKI), Chongqing VIP, Wanfang, PubMed, and SinoMed. The most frequently used TCM and their efficacy in PLC treatment were summarized. Based on the inclusion and exclusion criteria, 33 articles were selected. Overall, the efficacy of the combination of TCM and Western medicines in the treatment of PLC was higher than that in the control groups (i.e. treatment with Western medicines alone) (65.11% vs. 44.31%, P < .05). Among the 33 selected articles, 11 were investigated for TCM preparation (marketed drugs) and 22 for TCM formulas. In total, 102 types of TCM (single herbs) were used to treat PLC. The top five most frequently used TCM were Poria (14.71%), Astragali radix (13.73%), Atractylodis Macrocephalae Rhizoma (12.75%), Bupleuri radix (12.75%), and Glycyrrhizae radix et Rhizoma (11.76%). Of the 102 types of TCM, tonics were the most frequently used categories, followed by heat-clearing medicines, blood-invigorating medicines, and stasis-resolving medicines. Of 207 papers, 174 (84.06%) could not be subjected to statistical analysis due to research quality. Further high-quality research on herb sources, formula components and dosage, toxicology, and ethics of TCM is necessary. In conclusion, TCM play a promising role in the treatment and management of PLC, although further investigations are warranted.
topic Traditional Chinese medicines
Primary liver cancer
Integrative medicine
Clinical research
url http://www.sciencedirect.com/science/article/pii/S2095754821000442
work_keys_str_mv AT kaiqiliu progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer
AT hongliangli progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer
AT jufengduan progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer
AT xiaojingchen progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer
AT xiongjieyu progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer
AT xianhewang progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer
AT mingliu progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer
AT beili progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer
AT minglunli progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer
AT yibinfeng progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer
AT xiaojuncai progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer
AT xuanbinwang progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer
_version_ 1721206101445181440
spelling doaj-7252d3e2ffe44d9b8a836564a1e18de32021-08-16T04:16:24ZengElsevierJournal of Traditional Chinese Medical Sciences2095-75482021-07-0183173185Progress in clinical research on the integration of Chinese and Western medicines for treating primary liver cancerKaiqi Liu0Hongliang Li1Jufeng Duan2Xiaojing Chen3Xiongjie Yu4Xianhe Wang5Ming Liu6Bei Li7Minglun Li8Yibin Feng9Xiaojun Cai10Xuanbin Wang11Laboratory of Chinese Herbal Pharmacology, Oncology Center, Renmin Hospital; School of Pharmacy, Hubei University of Medicine, Shiyan, 442000, ChinaLaboratory of Chinese Herbal Pharmacology, Oncology Center, Renmin Hospital; School of Pharmacy, Hubei University of Medicine, Shiyan, 442000, ChinaLaboratory of Chinese Herbal Pharmacology, Oncology Center, Renmin Hospital; School of Pharmacy, Hubei University of Medicine, Shiyan, 442000, ChinaLaboratory of Chinese Herbal Pharmacology, Oncology Center, Renmin Hospital; School of Pharmacy, Hubei University of Medicine, Shiyan, 442000, ChinaLaboratory of Chinese Herbal Pharmacology, Oncology Center, Renmin Hospital; School of Pharmacy, Hubei University of Medicine, Shiyan, 442000, ChinaLaboratory of Chinese Herbal Pharmacology, Oncology Center, Renmin Hospital; School of Pharmacy, Hubei University of Medicine, Shiyan, 442000, ChinaLaboratory of Chinese Herbal Pharmacology, Oncology Center, Renmin Hospital; School of Pharmacy, Hubei University of Medicine, Shiyan, 442000, ChinaBiomedical Research Institute; Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, 442000, ChinaDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, 81377, GermanySchool of Chinese Medicine, The University of Hong Kong, Hong Kong, ChinaLaboratory of Chinese Herbal Pharmacology, Oncology Center, Renmin Hospital; School of Pharmacy, Hubei University of Medicine, Shiyan, 442000, ChinaLaboratory of Chinese Herbal Pharmacology, Oncology Center, Renmin Hospital; School of Pharmacy, Hubei University of Medicine, Shiyan, 442000, China; Biomedical Research Institute; Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, 442000, China; Corresponding author.Primary liver cancer (PLC) is one of the most common malignant tumors in China. PLC is characterized by insidious onset, rapid progress, poor quality of life, and short survival time. Notably, current treatment strategies remain unsatisfactory. Traditional Chinese medicines (TCM) have been used to treat a variety of diseases, including liver diseases, for more than 2000 years. In this study, we performed a review of the use frequency and clinical efficacy of TCM in treating PLC. Relevant literature from January 1, 2009, to January 1, 2021 was retrieved from network databases of China National Knowledge Infrastructure (CNKI), Chongqing VIP, Wanfang, PubMed, and SinoMed. The most frequently used TCM and their efficacy in PLC treatment were summarized. Based on the inclusion and exclusion criteria, 33 articles were selected. Overall, the efficacy of the combination of TCM and Western medicines in the treatment of PLC was higher than that in the control groups (i.e. treatment with Western medicines alone) (65.11% vs. 44.31%, P < .05). Among the 33 selected articles, 11 were investigated for TCM preparation (marketed drugs) and 22 for TCM formulas. In total, 102 types of TCM (single herbs) were used to treat PLC. The top five most frequently used TCM were Poria (14.71%), Astragali radix (13.73%), Atractylodis Macrocephalae Rhizoma (12.75%), Bupleuri radix (12.75%), and Glycyrrhizae radix et Rhizoma (11.76%). Of the 102 types of TCM, tonics were the most frequently used categories, followed by heat-clearing medicines, blood-invigorating medicines, and stasis-resolving medicines. Of 207 papers, 174 (84.06%) could not be subjected to statistical analysis due to research quality. Further high-quality research on herb sources, formula components and dosage, toxicology, and ethics of TCM is necessary. In conclusion, TCM play a promising role in the treatment and management of PLC, although further investigations are warranted.http://www.sciencedirect.com/science/article/pii/S2095754821000442Traditional Chinese medicinesPrimary liver cancerIntegrative medicineClinical research